Mattern Wealth Management LLC Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

Mattern Wealth Management LLC boosted its position in Johnson & Johnson (NYSE:JNJGet Rating) by 0.7% during the third quarter, HoldingsChannel.com reports. The fund owned 27,512 shares of the company’s stock after buying an additional 198 shares during the quarter. Johnson & Johnson makes up 1.8% of Mattern Wealth Management LLC’s portfolio, making the stock its 9th biggest position. Mattern Wealth Management LLC’s holdings in Johnson & Johnson were worth $4,494,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Red Wave Investments LLC lifted its holdings in Johnson & Johnson by 2.0% in the second quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock valued at $530,000 after buying an additional 59 shares during the period. Argus Investors Counsel Inc. lifted its holdings in Johnson & Johnson by 0.6% in the second quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock valued at $1,941,000 after buying an additional 61 shares during the period. Alta Capital Management LLC lifted its holdings in Johnson & Johnson by 0.4% in the second quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock valued at $2,808,000 after buying an additional 61 shares during the period. Paces Ferry Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 0.7% in the third quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock valued at $1,425,000 after buying an additional 62 shares during the period. Finally, Mason & Associates Inc raised its holdings in shares of Johnson & Johnson by 4.9% during the third quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after purchasing an additional 62 shares during the period. 67.94% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on JNJ shares. Barclays started coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective on the stock. Raymond James dropped their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a report on Wednesday, October 19th. Sanford C. Bernstein dropped their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Citigroup boosted their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Finally, StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $181.75.

Johnson & Johnson Trading Down 0.5 %

Shares of JNJ stock opened at $168.74 on Monday. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The company has a 50-day simple moving average of $176.14 and a two-hundred day simple moving average of $171.20. The company has a market capitalization of $441.17 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 3.19 and a beta of 0.56.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.68%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s payout ratio is 62.95%.

Insiders Place Their Bets

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Johnson & Johnson news, EVP Ashley Mcevoy sold 73,323 shares of the business’s stock in a transaction dated Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total value of $12,865,986.81. Following the transaction, the executive vice president now directly owns 41,813 shares in the company, valued at $7,336,927.11. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 233,611 shares of company stock valued at $40,960,735. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.